Brief: Medicure Announces Pivotal Phase 3 Trial IND Filing With FDA For Treatment Of Seizures Associated With PNPO Deficiency
07/01/2021 23:30
Jan 7 (Reuters) - Medicure Inc MPH.V :
* MEDICURE ANNOUNCES PIVOTAL PHASE 3 TRIAL IND FILING WITH
FDA FOR
TREATMENT OF SEIZURES ASSOCIATED WITH PYRIDOX(AM)INE
5'-PHOSPHATE OXIDASE (PNPO) DEFICIENCY
Source text for Eikon: ID:nCNWhd430a
Further company coverage: MPH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicure
See all newsBrief: Medicure Announces Resignation Of Board Member And Grant Of Stock Options
Brief: Medicure Posts Qtrly Earnings Per Share $0.11
Brief: Medicure Reports Financial Results For Quarter Ended June 30, 2022
Brief: Medicure Announces Resignation Of CFO And Succession Plan
Brief: Algernon Pharmaceuticals Appoints James Kinley As CFO Effective From December 1, 2021